重症肌无力的治疗现状  

Circumstance of the therapy of myasthenia gravis

作　　者：于逢春[1] 余华锋[1] 

机构地区：[1]北京同仁医院神经内科

出　　处：《中国处方药》2004年第2期63-66,共4页Journal of China Prescription Drug

摘　　要：Myasthenia gravis is a most common neurological disease with autoimmune disorder. Most ofthe research on myasthenia gravis has focused on treatment . we will assess the effect of the treatments ofmyasthenia gravis, which including corticosteroids, immunosuppressive , IV immunoglobulin , plasmapheresisand thymectomy. The treatment for patients with myasthenia gravis usually depends on age, clinical charac-teristics and thymoma or nonthymoma～related MG and so on.Myasthenia gravis is a most common neurological disease with autoimmune disorder. Most ofthe research on myasthenia gravis has focused on treatment . we will assess the effect of the treatments ofmyasthenia gravis, which including corticosteroids, immunosuppressive , IV immunoglobulin , plasmapheresisand thymectomy. The treatment for patients with myasthenia gravis usually depends on age, clinical charac-teristics and thymoma or nonthymoma～related MG and so on.

关 键 词：重症肌无力 治疗 MG 免疫抑制剂 免疫球蛋白 

分 类 号：R746.1[医药卫生—神经病学与精神病学]